Longeveron Inc. (“Longeveron”) is a leading clinical stage biotechnology company developing cell therapies for chronic aging-related diseases and other life-threatening conditions, for which there are no approved treatments.
With its Initial Public Offering, the management is in a comfortable position to complete the current ongoing trials and to initiate around four additional Phase 2 clinical trials, which may subsequently lead to commercialization and a huge spike in revenues.
Moreover, the management has completed its 10 patient multi-center open-label Phase 1 clinical trial, and is inspecting Phase 1 top-line results in the second quarter of this year.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.